SION
Sionna Therapeutics Inc
$
23.230
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
23.690
Open
22.460
VWAP
23.10
Vol
362.06K
Mkt Cap
1.03B
Low
22.460
Amount
8.36M
EV/EBITDA(TTM)
--
Total Shares
44.12M
EV
717.87M
EV/OCF(TTM)
--
P/S(TTM)
--
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Show More
4 Analyst Rating
62.16% Upside
Wall Street analysts forecast SION stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is 37.67 USD with a low forecast of 22.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
62.16% Upside
Current: 23.230
Low
22.00
Averages
37.67
High
46.00
62.16% Upside
Current: 23.230
Low
22.00
Averages
37.67
High
46.00
JonesResearch
initiated
$46
2025-09-08
Reason
JonesResearch
Price Target
$46
2025-09-08
initiated
Reason
JonesResearch initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $46 price target. Sionna is clinical stage biotech advancing novel cystic fibrosis drugs, the analyst tells investors in a research note. The firm says the company has developed two NBD1 stabilizers, SION-451 and SION-719, which, when in combination with complementary modulators, are likely superior to the standard of care, Vertex's (VRTX) Trikafta.
RBC Capital
Brian Abrahams
Sector Perform
initiated
$22
2025-09-03
Reason
RBC Capital
Brian Abrahams
Price Target
$22
2025-09-03
initiated
Sector Perform
Reason
RBC Capital analyst Brian Abrahams initiated coverage of Sionna Therapeutics with a Sector Perform rating and $22 price target. The company's CFTR modulators could position it as a long-term key player in the cystic fibrosis space, the analyst tells investors in a research note. However, existing treatments create a high bar and there are questions as to how meaningfully de-risking Sionna's next set of clinical data in mid-2026 will be, the analyst tells investors in a research note. As such, RBC would wait for more progress before stepping into the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sionna Therapeutics Inc (SION.O) is -11.05, compared to its 5-year average forward P/E of -6.77. For a more detailed relative valuation and DCF analysis to assess Sionna Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.77
Current PE
-11.05
Overvalued PE
-3.61
Undervalued PE
-9.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.10
Current EV/EBITDA
-7.08
Overvalued EV/EBITDA
-2.84
Undervalued EV/EBITDA
-7.37
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
-21.91M
Operating Profit
FY2025Q2
-18.07M
Net Income after Tax
FY2025Q2
-0.41
EPS - Diluted
FY2025Q2
-18.15M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
20.1M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SION News & Events
Events Timeline
2025-09-08 (ET)
2025-09-08
08:23:09
Sionna Therapeutics names Caroline Stark Beer as Chief Business Officer
2025-08-25 (ET)
2025-08-25
07:07:17
Sionna Therapeutics reports initial dosing of subjects in Phase 1 trial for SION-451
2025-08-11 (ET)
2025-08-11
07:04:32
Sionna Therapeutics reports Q2 EPS (41c) vs ($2.71) last year
Sign Up For More Events
Sign Up For More Events
News
4.0
09-15NASDAQ.COMEverything You Should Know About the Rating Upgrade to Buy for Sionna Therapeutics, Inc. (SION)
4.0
09-08BenzingaJones Trading Begins Coverage of Sionna Therapeutics with a Buy Rating and Sets Price Target at $46
4.0
09-03BenzingaRaymond James Begins Coverage of Sionna Therapeutics with a Strong Buy Rating and Sets Price Target at $45
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
416.850
USD
-2.12%
ORCL
Oracle Corp
296.620
USD
-1.59%
WMT
Walmart Inc
103.600
USD
-0.64%
AAPL
Apple Inc
237.880
USD
-0.46%
AVGO
Broadcom Inc
345.350
USD
-0.24%
META
Meta Platforms Inc
780.250
USD
+0.58%
NVDA
NVIDIA Corp
176.240
USD
+3.49%
AMZN
Amazon.com Inc
231.230
USD
-0.17%
MSFT
Microsoft Corp
508.450
USD
-0.31%
XOM
Exxon Mobil Corp
113.930
USD
-1.18%
FAQ
What is Sionna Therapeutics Inc (SION) stock price today?
The current price of SION is 23.23 USD — it has increased 4.55 % in the last trading day.
What is Sionna Therapeutics Inc (SION)'s business?
What is the price predicton of SION Stock?
What is Sionna Therapeutics Inc (SION)'s revenue for the last quarter?
What is Sionna Therapeutics Inc (SION)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sionna Therapeutics Inc (SION)'s fundamentals?
How many employees does Sionna Therapeutics Inc (SION). have?